Multimodal treatment in Glioblastomas

Authors

DOI:

https://doi.org/10.5222/sscd.2021.83703

Keywords:

Glioblastoma, TTF, tumor treating fields, viral oncolysis, immune check point inhibitors, CAR-T, mesenchymal stem cells

Abstract

Glioblastomas are the most common primary brain tumors. Despite aggressive resection, radiotherapy and concomitant chemotheraphy overall survival is 14-16 months, and 5 year survivial rate is only 2%. The poor prognosis required development of new treatment modalities. Tumor Treating Fields, molecularly targetted drugs, antiangiogenic molecules, immune checkpoint inhibitors, tumor vaccines, Chimeric Antigen Receptor-T cell, viral theraphy and oncolytic viruse and mesenchymal stem cell vectors are some of the modalities that are currently being developed.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Published

2021-04-30

How to Cite

1.
Çetin E, Kabataş S. Multimodal treatment in Glioblastomas. J Nervous Sys Surgery [Internet]. 2021 Apr. 30 [cited 2022 May 16];7(1):14-25. Available from: https://sscdergisi.org/index.php/sscd/article/view/11

Issue

Section

Review